Koichiro Fujisue

Koichiro Fujisue

Auto-generated profile, based on publicly available information

Koichiro Fujisue

Department of Cardiovascular Medicine, Graduate School of Medical Sciences, Kumamoto University , 1-1-1 Honjo, Chuo-ku, Kumamoto 860-8556 , Japan

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2014 in International Journal of Cardiology
Verified
Journal Article
Closed access
YHYoshihiro Hirata
Yoshihiro Hirata
SSSeigo Sugiyama
Seigo Sugiyama
EYEiichiro Yamamoto
Eiichiro Yamamoto
YMYasushi Matsuzawa
Yasushi Matsuzawa
EAEiichi Akiyama
Eiichi Akiyama
HOHisao Ogawa
Hisao Ogawa

1 December 2016 in Atherosclerosis
Verified
Journal Article
Closed access
EYEiichiro Yamamoto
Eiichiro Yamamoto
SSSeigo Sugiyama
Seigo Sugiyama
YHYoshihiro Hirata
Yoshihiro Hirata
TTTakanori Tokitsu
Takanori Tokitsu
NTNoriaki Tabata
Noriaki Tabata
SHSeiji Hokimoto
Seiji Hokimoto

1 January 2022 in The Korean Journal of Internal Medicine
Verified
Journal Article
Open access
PDF file
KEKoichi Egashira
Koichi Egashira
DSDaisuke Sueta
Daisuke Sueta
TKTakashi Komorita
Takashi Komorita
EYEiichiro Yamamoto
Eiichiro Yamamoto
HUHiroki Usuku
Hiroki Usuku
KTKenichi Tsujita
Kenichi Tsujita
Background/Aims: The Heart Failure Association (HFA)-PEFF score is recognized as a simple method to diagnose heart failure (HF) with preserved ejection fraction (HFpEF). This study aimed to evaluate the relationship between HFA-PEFF scores and cardiovascular outcomes in HFpEF patients.Methods: A total of 502 consecutive HFpEF patients were prospectively observed for up to 1,500 days. Cardiovascular outcomes were compared between two groups of patients, defined by their HFA-PEFF scores: those who scored 2–4 (the intermediate-score group) and those who scored 5–6 group (the high-score group). Overall, 236 cardiovascular events were observed during the follow-up period (median, 1,159 days).Results: Kaplan-Meier analysis showed that there were significant differences in composite cardiovascular events and HF-related events between the intermediate-score group and the high-score group (p = 0.003 and p < 0.001, respectively). Multivariate Cox proportional hazards analysis showed that the HFA-PEFF scores significantly predicted future HF-related events (hazard ratio, 1.66; 95% confidence interval [CI], 1.11 to 2.50; p = 0.014); receiver operating characteristic analysis confirmed this relationship (area under the curve, 0.633; 95% CI, 0.574 to 0.692; p < 0.001). The cutoff HFA-PEFF score for the identification of HF-related events was 4.5. Decision curve analysis revealed that combining the HFA-PEFF score with conventional prognostic factors improved the prediction of HF-related events.Conclusions: HFA-PEFF scores may be useful for predicting HF-related events in HFpEF patients.

3 June 2024 in EP Europace
Verified
Journal Article
Open access
PDF file
HKHisanori Kanazawa
Hisanori Kanazawa
STSeiji Takashio
Seiji Takashio
THTadashi Hoshiyama
Tadashi Hoshiyama
MIMiwa Ito
Miwa Ito
SKShozo Kaneko
Shozo Kaneko
KTKenichi Tsujita
Kenichi Tsujita
Wild-type transthyretin amyloid cardiomyopathy (ATTRwt-CM) is often accompanied by atrial fibrillation (AF), atrial flutter (AFL), and atrial tachycardia (AT), which are difficult to control because beta-blockers and antiarrhythmic drugs can worsen heart failure (HF). This study aimed to investigate the outcomes of catheter ablation (CA) for AF/AFL/AT in patients with ATTRwt-CM and propose a treatment strategy for CA. A cohort study was conducted on 233 patients diagnosed with ATTRwt-CM, including 54 who underwent CA for AF/AFL/AT. The background of each arrhythmia and the details of the CA and its outcomes were investigated. The recurrence-free rate of AF/AFL/AT overall in ATTRwt-CM patients with multiple CA was 70.1% at 1-year, 57.6% at 2-year, and 44.0% at 5-year follow-up, but CA significantly reduced all-cause mortality [hazard ratio (HR): 0.342, 95% confidence interval (CI): 0.133–0.876, P = 0.025], cardiovascular mortality (HR: 0.378, 95% CI: 0.146–0.981, P = 0.045), and HF hospitalization (HR: 0.488, 95% CI: 0.269–0.889, P = 0.019) compared with those without CA. There was no recurrence of the cavotricuspid isthmus (CTI)–dependent AFL, non-CTI–dependent simple AFL terminated by one linear ablation, and focal AT originating from the atrioventricular (AV) annulus or crista terminalis eventually. Twelve of 13 patients with paroxysmal AF and 27 of 29 patients with persistent AF did not have recurrence as AF. However, all three patients with non-CTI–dependent complex AFL not terminated by a single linear ablation and 10 of 13 cases with focal AT or multiple focal ATs originating beyond the AV annulus or crista terminalis recurred even after multiple CA. The outcomes of CA for ATTRwt-CM were acceptable, except for multiple focal AT and complex AFL. Catheter ablation may be aggressively considered as a treatment strategy with the expectation of improving mortality and hospitalization for HF.

1 July 2019 in Medicine
Verified
Journal Article
Open access
KFKoichiro Fujisue
Koichiro Fujisue
TTTakanori Tokitsu
Takanori Tokitsu
EYEiichiro Yamamoto
Eiichiro Yamamoto
DSDaisuke Sueta
Daisuke Sueta
MTMasafumi Takae
Masafumi Takae
KTKenichi Tsujita
Kenichi Tsujita
The prognostic significance of systemic atherothrombosis in heart failure (HF) with preserved ejection fraction (HFpEF) remains unclear. This study aimed to investigate the relation between the presence of polyvascular disease (PVD) and cardiovascular outcomes in HFpEF patients. A total of 510 consecutive HFpEF patients were prospectively observed for up to 1500 days or until occurrence of cardiovascular events. PVD was defined as ≥2 coexistence of coronary artery disease, peripheral arterial disease, and cerebrovascular disease. Overall, 124 cardiovascular events were observed during follow-up (median: 1430 days). Kaplan–Meier curve showed HFpEF with PVD (n = 84) experienced more cardiovascular events than did those without PVD patients (44.0% vs 20.4%, log-rank: P < .001). Multivariable Cox proportional hazards analysis with significant factors from univariate analysis showed the presence of PVD (hazard ratio [HR]: 2.875, 95% [CI]: 1.894–4.365, P < .001), previous HF hospitalization (HR: 1.578, 95% CI: 1.031–2.414, P = .036), hemoglobin (HR: 0.889, 95% CI: 0.805–0.983, P = .021), serum sodium (HR: 0.946, 95% CI 0.896–1.000, P = .048), ln-BNP (per 1.0, HR: 1.255, 95% CI: 1.055–1.494, P = .010), and E/e’ (HR: 1.047, 95% CI: 1.020–1.075, P < .001) significantly predicted future cardiovascular events. Multivariable Cox hazard analysis with 4 established factors (age, BNP, diabetes mellitus, and previous HF hospitalization) from the I-PRESERVE (Irbesartan in HFpEF) study showed PVD was independently associated with cardiovascular events in HFpEF patients (HR: 2.562, 95% CI: 1.715–3.827, P < .001). The presence of PVD is significantly associated with cardiovascular events in HFpEF, suggesting the importance of screening PVD in HFpEF.

1 June 2021 in IJC Heart & Vasculature
Verified
Journal Article
Open access
KEKoichi Egashira
Koichi Egashira
DSDaisuke Sueta
Daisuke Sueta
MTMai Tomiguchi
Mai Tomiguchi
MKMasafumi Kidoh
Masafumi Kidoh
SOSeitaro Oda
Seitaro Oda
KTKenichi Tsujita
Kenichi Tsujita
Cardiotoxicity in the late phase after anthracycline drugs administration remains to be defined. Of the 44 patients who received anthracycline treatment, 7 were found to have cancer therapeutics–related cardiac dysfunction (CTRCD). The global longitudinal strain determined by echocardiography and myocardial extracellular volume fraction (ECV) determined by cardiac computed tomography (CCT) of the CTRCD(+) group were significantly higher than those of the control group and CTRCD(-) group, whereas there were no significant differences between the control and CTRCD(-) groups. Our findings indicated that CCT may be a tool comparable to echocardiography, indicating the effective evaluation of CTRCD by CCT.